ProCE Banner Activity

Expert Guidance on Personalizing Treatment of CLL: Overcoming the Conundrum of Multiple New Agents

Slideset Download
Download these slides from our local live meeting series on CLL to review the most recent clinical data on new agents in both frontline and relapsed/refractory CLL.

Released: June 19, 2019

Expiration: June 17, 2020

No longer available for credit.

Share

Faculty

John M. Burke

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

Nicole Lamanna

Nicole Lamanna, MD

Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Pharmacyclics an AbbVie Company

Verastem Oncology

Partners

CLL Society

ProCE Banner

Faculty Disclosure

Primary Author

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

John M. Burke, MD, has disclosed that he has received has received consulting fees from AbbVie, AstraZeneca, Bayer, Celgene, Genentech, Gilead, Tempus, and Seattle Genetics and fees for non-CME/CE services from Seattle Genetics.

Nicole Lamanna, MD

Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Nicole Lamanna, MD, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, BeiGene, Celgene, Genentech, Janssen, and Pharmacyclics and funds for research support from AbbVie, Acerta, AstraZeneca, BeiGene, Celgene, Genentech, Infinity, Janssen, Oncternal, Pharmacyclics, TG Therapeutics, and Verastem.